Showing results (11-20 of 1,548) with videos related to

Sort By:
Pageof 155
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patientsGabriella Ferrandina, Gian Franco Zannoni, Enrica Martinelli, et al.
Molecular Cancer Therapeutics|January 12, 2008
From plasma membrane to cytoskeleton: a novel function for semaphorin 6ASilvia Prislei, Simona Mozzetti, Flavia Filippetti, et al.
BMC Immunology|August 29, 2009
Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cellsGiuseppina Bonanno, Andrea Mariotti, Annabella Procoli, et al.
Cancer Research|March 23, 2005
The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistanceCristiano Ferlini, Giuseppina Raspaglio, Simona Mozzetti, et al.
Biochemical Pharmacology|September 12, 2012
Gli family transcription factors are drivers of patupilone resistance in ovarian cancerSimona Mozzetti, Enrica Martinelli, Giuseppina Raspaglio, et al.
Gene|January 8, 2008
Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking regionGiuseppina Raspaglio, Flavia Filippetti, Silvia Prislei, et al.
Transfusion|September 11, 2015
A new standardized clinical-grade protocol for banking human umbilical cord tissue cellsRaffaella Fazzina, Andrea Mariotti, Annabella Procoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support: clinical implicationsGabriella Ferrandina, Luca Pierelli, Alessandro Perillo, et al.
Molecular Pharmacology|June 20, 2003
Bcl-2 down-regulation is a novel mechanism of paclitaxel resistanceCristiano Ferlini, Giuseppina Raspaglio, Simona Mozzetti, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 30, 2020
KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancerMarta De Donato, Gabriele Babini, Simona Mozzetti, et al.
Pageof 155